Simulations Plus’ (SLP) “Neutral” Rating Reiterated at BTIG Research

BTIG Research reaffirmed their neutral rating on shares of Simulations Plus (NASDAQ:SLP) in a research report report published on Wednesday,Benzinga reports.

SLP has been the subject of several other research reports. Wall Street Zen cut Simulations Plus from a “buy” rating to a “hold” rating in a report on Saturday, June 13th. Weiss Ratings upgraded shares of Simulations Plus from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, July 10th. Craig Hallum lowered shares of Simulations Plus from a “buy” rating to a “hold” rating and set a $18.50 price objective on the stock. in a report on Thursday, June 18th. Finally, William Blair cut shares of Simulations Plus from an “outperform” rating to a “market perform” rating in a research report on Wednesday, June 17th. Seven equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce” and an average target price of $17.25.

Simulations Plus Price Performance

Shares of Simulations Plus stock opened at $18.50 on Wednesday. Simulations Plus has a fifty-two week low of $11.09 and a fifty-two week high of $21.01. The firm has a market cap of $374.16 million, a PE ratio of 46.25 and a beta of 1.31. The business’s fifty day moving average is $18.41 and its two-hundred day moving average is $16.72.

Simulations Plus (NASDAQ:SLP) last posted its quarterly earnings data on Thursday, July 9th. The technology company reported $0.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.07. The business had revenue of $21.89 million for the quarter, compared to analysts’ expectations of $20.90 million. Simulations Plus had a return on equity of 13.50% and a net margin of 9.88%.

Institutional Investors Weigh In On Simulations Plus

A number of institutional investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC grew its stake in Simulations Plus by 26.0% during the second quarter. GAMMA Investing LLC now owns 2,831 shares of the technology company’s stock worth $52,000 after buying an additional 585 shares during the period. Bank of New York Mellon Corp increased its position in shares of Simulations Plus by 1.3% in the first quarter. Bank of New York Mellon Corp now owns 63,592 shares of the technology company’s stock worth $752,000 after acquiring an additional 844 shares in the last quarter. Farther Finance Advisors LLC raised its stake in shares of Simulations Plus by 242.6% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,384 shares of the technology company’s stock valued at $26,000 after acquiring an additional 980 shares during the period. Integrated Wealth Concepts LLC purchased a new position in shares of Simulations Plus in the 2nd quarter valued at $26,000. Finally, Hsbc Holdings PLC lifted its holdings in shares of Simulations Plus by 6.1% during the 2nd quarter. Hsbc Holdings PLC now owns 28,116 shares of the technology company’s stock valued at $520,000 after acquiring an additional 1,622 shares in the last quarter. Hedge funds and other institutional investors own 78.08% of the company’s stock.

About Simulations Plus

Simulations Plus, Inc develops software and provides services that support pharmaceutical research, drug development and regulatory decision-making. Its technologies help scientists model how drug compounds behave in the body, assess formulation and delivery characteristics, and evaluate potential safety and efficacy outcomes.

The company’s software portfolio includes GastroPlus, a platform for physiologically based pharmacokinetic and pharmacodynamic modeling; ADMET Predictor, which forecasts absorption, distribution, metabolism, excretion and toxicity properties; and DDDPlus, which simulates drug dissolution and dosage-form performance.